| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 15 | -459,162 | 100% | $87.17 | -$40,024,533 |
| Net | -15 | -459,162 | -100% | -$40,024,533 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| MERIDIAN VENTURE PARTNERS II LP | 10%+ Owner | $102,678,978 | 16 Aug 2023 | ||
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS, Director | $48,029,229 | -$17,914,322 | -27% | 20 Aug 2025 |
| Nikhil Lalwani | PRESIDENT & CEO, Director | $39,338,831 | -$4,894,573 | -11% | 12 Aug 2025 |
| Chad Gassert | Svp Corp. Dev. & Strategy | $20,690,254 | -$3,051,835 | -13% | 12 Nov 2025 |
| STEPHEN P. CAREY | Svp & Cfo | $15,566,878 | -$4,303,500 | -22% | 12 Aug 2025 |
| James G. Marken | Svp Ops & Prod Dev | $7,977,023 | 07 Jun 2024 | ||
| Ori Gutwerg | Svp, Generics | $7,686,390 | -$884,161 | -10% | 12 Aug 2025 |
| Christopher Mutz | Head Of Rare Disease | $6,487,312 | -$241,800 | -3.6% | 14 May 2025 |
| Meredith W. Cook | Sr. Vp, General Counsel & Sec. | $6,271,959 | -$373,065 | -5.6% | 13 Jan 2026 |
| Patrick D. Walsh | Director | $5,369,171 | -$1,552,354 | -22% | 13 Nov 2025 |
| Krista Davis | Svp, Chief Hr Officer | $4,825,673 | -$634,652 | -12% | 18 Dec 2025 |
| Thomas Andrew Rowland | Svp, Head Established Brands | $3,496,453 | -$426,407 | -11% | 12 Aug 2025 |
| THOMAS HAUGHEY | Director | $3,138,249 | -$1,661,972 | -35% | 12 Aug 2025 |
| Robert E. Brown Jr. | Director | $2,766,745 | 27 Apr 2022 | ||
| DAVID NASH | Director | $2,176,383 | 23 May 2023 | ||
| Antonio R. Pera | Director | $2,151,340 | -$1,178,729 | -35% | 03 Sep 2025 |
| Jeanne Thoma | Director | $2,080,002 | -$1,920,370 | -48% | 18 Aug 2025 |
| RENEE P. TANNENBAUM | Director | $2,041,490 | -$146,070 | -6.7% | 05 Dec 2025 |
| Matthew J. Leonard | Director | $622,015 | -$840,723 | -57% | 25 Aug 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|